Skip to main content
. 2014 Feb 25;15:65. doi: 10.1186/1745-6215-15-65

Table 7.

Consent processes and understanding of the trial (Household survey)

 
Site A
Site B
Site C
Total
  n = 67 (%) n = 33 (%) n = 100 (%) n = 200 (%)
Main purpose of the trial
 
 
 
 
Provide treatment/help to participating children
32 (47.8)
18 (54.5)
71 (71.0)
121 (60.5)
Learn about potential for preventing malaria
27 (40.3)
12 (36.4)
23 (23.0)
62 (31.0)
DK
3 (4.5)
1 (3.0)
3 (3.0)
7 (3.5)
Other activities
2 (3.0)
0
2 (2.0)
4 (2.0)
Missing/data not clear to code
3(4.5)
2 (6.1)
1 (1.0)
6 (3.0)
Did all children in the trial get a malaria vaccine?
 
 
 
 
Yes
38 (56.7)
19 (57.6)
63 (63.0)
120 (60.0)
No
12 (17.9)
6 (18.2)
11 (11.0)
29 (14.5)
DK
17 (25.4)
8 (24.2)
24 (24.0)
49 (24.5)
Missing data
0
0
2 (2.0)
2 (1.0)
Do you think children who got trial vaccines are still able to get malaria?
 
 
 
 
Yes
10 (14.9)
5 (15.2)
15 (15.0)
30 (15.0)
No
32 (47.8)
17 (51.5)
56 (56.0)
105 (52.5)
DK
25 (37.3)
11 (33.3)
28 (28.0)
64 (32.0)
Missing data
0 (0)
0
1 (1.0)
1 (0.5)
Would consider participating in future similar trial?
 
 
 
 
Agree
45 (67.2)
20 (60.6)
80 (80.0)
145 (72.5)
Not agree
2 (3.0)
0
0
2 (1.0)
Indifferent/DKa
20 (29.9)
13 (39.4)
20 (20.0)
53 (26.5)
Content with decision to enrol your child in the trial?
 
 
 
 
Yes
61 (91.0)
31 (93.9)
94 (94.0)
186 (93.0)
No
4 (6.0)
0
2 (2.0)
6 (3.0)
Indifferent
2 (3.0)
2 (6.1)
4 (4.0)
8 (4.0)
Most important reasons for enrolling in trial (top five)
 
 
 
 
Access to free treatment
18 (26.9)
10 (30.3)
35 (35.0)
63 (31.5)
Access to better and quality services
9 (13.4)
6 (18.2)
25 (25.0)
40 (20.0)
Vaccine beneficial
12 (17.9)
5 (15.2)
13 (13.0)
30 (15.0)
Detailed explanation of the study
5 (7.5)
3 (9.1)
7 (7.0)
15 (7.5)
Previous experience/interaction with KEMRI 3 (4.5) 4 (12.1) 6 (6.0) 13 (6.5)

a Here most people reported they would first want to hear more about what the trial would involve at the point of information giving before making their decision.

DK; do not know.